Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Trial Profile

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Trichostatin A (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2018 According to a Vanda Pharmaceuticals media release, first patient was randomised in this trial in October 2018.
    • 07 Nov 2018 Status changed from planning to recruiting, as reported in the Vanda Pharmaceuticals media release.
    • 14 Feb 2018 According to a Vanda Pharmaceuticals media release, trial is expected to start in the second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top